Newsroom | 1393 results

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found...

MIAMI--(BUSINESS WIRE)--A new study from the University of Miami Public Health Policy Lab and the AHF Global Public Health Institute sheds light on why public trust broke down during the COVID-19 pandemic—and what can be done to rebuild it before the next health emergency. Drawing on interviews with government, academic, and private-sector leaders across Florida, the study found that distrust in public health grew due to a lack of transparency, political tensions, and inconsistent communication...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O’Day, C...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors. FULL-YEAR 2026 REVENUE GUIDANCE(2) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to app...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer...

WALTON OAKS--(BUSINESS WIRE)--Pfizer Ltd today shared findings from a survey developed and funded by Pfizer but conducted independently by OnePoll, with 2,000 people aged over 65 across the UK between 21-27 November 2025, which reveals how older adult respondents see avoiding respiratory infections (COVID, pneumonia, RSV, flu) as essential to protecting both their freedom and their role at the heart of family and community life.1 The survey underscores the strong motivation older adult responde...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transformation (RT), a rare complication in which chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma...

CIUDAD DE MÉXICO--(BUSINESS WIRE)--Sin cooperación regional, Latinoamérica no podrá enfrentar adecuadamente la próxima emergencia sanitaria. Este fue el mensaje central del panel de alto nivel organizado por el Instituto AHF de Salud Pública Global y el Laboratorio de Políticas Públicas en Salud de la Universidad de Miami, en el que líderes de la región coincidieron en que es urgente construir una arquitectura latinoamericana capaz de responder como bloque ante futuras crisis sanitarias. El web...

MEXICO CITY--(BUSINESS WIRE)--Without regional cooperation, Latin America will not be able to adequately confront the next health emergency. This was the central message of the high-level panel organized by the AHF Global Public Health Institute and the University of Miami’s Public Health Policy Lab, where regional leaders agreed that it is urgent to build a Latin American architecture capable of responding as a bloc to future health crises. The webinar, moderated by Dr. Jorge Saavedra, Executi...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET) About Arcturus Founded in 2013 and based i...